All In Biotech

Drug Trial Radar · NCT03580369

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Last checked: Nov 20, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,072 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,072

Actual

Start

Oct 17, 2018

Primary completion

Jul 16, 2021

Study completion Jun 14, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo. The study population consisted of 1,072 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines. This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • LigelizumabBiological

    Liquid in vial

  • OmalizumabBiological

    Lyophilized powder for solution in vial

  • PlaceboOther

    Liquid in vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult SubjectsTime frame: Baseline, Week 12
  2. Mean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)Time frame: Baseline, Week 12

Locations

161 sites in 29 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Gilbert, Arizona

  • Novartis Investigative Site

    Litchfield Park, Arizona

  • Novartis Investigative Site

    Scottsdale, Arizona

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Bakersfield, California

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Long Beach, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Greenacres City, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Boise, Idaho

  • Novartis Investigative Site

    Evansville, Indiana

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Overland Park, Kansas

  • Novartis Investigative Site

    Bangor, Maine

  • Novartis Investigative Site

    Waldorf, Maryland

  • Novartis Investigative Site

    Clarkston, Michigan

  • Novartis Investigative Site

    Ypsilanti, Michigan

  • Novartis Investigative Site

    Plymouth, Minnesota

  • Novartis Investigative Site

    Asheville, North Carolina

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Tulsa, Oklahoma

  • Novartis Investigative Site

    Medford, Oregon

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Pflugerville, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    South Burlington, Vermont

  • Novartis Investigative Site

    Bahía Blanca, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Capital Federal, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Nueve De Julio, Argentina

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Vienna, Austria

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.